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S298 Poster Session II(IL-1b, IL-6, IL-8, IFN-g, MIF and TNF-a). We have observed
clinical differences in the rates of mixed chimerism and GVHD de-
pending on when the alemtuzumab is given. This data suggests that
the cytokine milieu may contribute to the development of GVHD
and Transplant Related Morbidity (TRM).
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OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION IN COMMUNITY CANCER CENTERS: SINGLE INSTITUTION EXPE-
RIENCE
Khaled, Y., Beredo, L., McEntee, S., Fondaw, M., Villegas, M.,
Mountford, K., Reddy, V. Florida Cancer Institute, Orlando, FL
Variability in outcomes after hematopoietic stem cell transplanta-
tion (HCT) due to differences in health care delivery is traditionally
referred to as ‘‘center effect’’. Data analysis by CIBMTR demon-
strated improved day 100 survival after related donor (RD) HCT
with greater physician involvement in patient’s care regardless of
medical school affiliation. We hypothesized that the greater physi-
cian involvement in patient’s care at our community transplant cen-
ter would compensate for the lack of infrastructure available to
academic centers and result in comparable outcomes.We retrospec-
tively reviewed the medical records of 50 consecutive patients who
underwent matched unrelated (MUD) HCT (n 5 26) or RD HCT
(n 5 24) for hematological malignancies between August 2007 andTable 1. Patients characteristic
Number of patients 50 (100%)
Age Median 56 (Range 23-71)
Patients above the age of 55 27 (54%)
Patients below the age of 55 23 ( 46%)
Match related (RD) 23 (46%)
Mismatched related 5/6 1 (2%)
Matched unrelated (MUD) 22 (44%)
Mismatched unrelated 4 (8%)
Male 30 (60%)
Female 20 (40%)
Diagnosis
AML/MDS 26 (52%)
ALL 8 (16%)
Myelofibrosis 2 (4%)
CLL 2 (4%)
T-cell prolymphocytic leukemia 2 (4%)
CML (accelarated phase) 1 (2%)
HD 2 (4%)
Severe aplastic anemia 1 (2%)
Non Hodgkins lymphoma 3 (6%)
Multiple myeloma 3 (6%)
Stem cell source Peripheral stem cells 50 (100%)
Status at transplant
Complete remission -1 20 (40%)
Complete remission-2 9 (18%)
Progressive disease 7 (14%)
Persistent disease 14 (28%)
Prior Transplants
Autologous 7; non tandem (14%)
Allogeneic related 5 (10%)
Cytogenetics
High Risk 28 (56%)
Normal 19 (38%)
Not available 3 (6%)
Charlson Comorbidity Index
Score 0 7 (14%)
Score 1-2 10 (20%)
Score 3-4 20(40%)
Score 5 and above 13 (26%)
Conditioning Regimens
Full Intensity (FIC) 20 (40%)
Reduced Intensity(RIC) 21(42%)
Non Myeloablative (NMA) 9 (18%)
GVHD, graft versus host disease; OS, overall survival; DFS, disease free
survival; NRM, non relapse mortality; NMA, Flu/TBI, RIC, FluBU-2/Flu-
Mel, FIC FluBU-4/BUCY/CYTBIApril 2010. GVHD prophylaxis used was Tacrolimus/Methotrexate
or Tacrolimus/Mycophenolate. MUD HCT recipients recieved
ATG in addition. Twenty one (42%) and twenty eight patients
(56%) of cohort had progressive/persistent disease and high risk cy-
togenetics at time of transplant respectively. Thirty three patients
(66%) had Charlson Co-morbidity index of 3 or more. Patients
characteristic is shown in the table below.
OS at 100 days and 1 year were 86% and 67% respectively. There
was no statistical difference in OS between RD and MUD; (83% vs.
88% at day 100 and 74% vs. 64% at 1 year for RD and MUD recip-
ients respectively, P5 0.85). DFSwas 55% at 1year. Again, there was
no statistical significance difference in DFS between RD and MUD
at 1 year (P5 0.48). The cumulative incidence of relapse was 16% at
1 year (21% for RD and12% for MUD). We found no difference in
the cumulative incidence of NRMbetween RD andMUD recipients
at day 100 (12%). In contrast, NRM was higher at 1 year in MUD
recipients of 34% vs. 25% for the RD recipients. The overall cumu-
lative incidence of acute GVHD grade II-IV was 47.8% with inci-
dence of severe GVHD grade III/IV of 16%. The cumulative
incidence of chronic GVHD was 67.6%.
Conclusions: Allogeneic HCT outcomes in the community seem to
be comparable to outcomes reported in literature. In this single in-
stitution experience, despite the absence of direct cause and effect re-
lationship, the greater involvement of physicians in the patient’s care
may have contributed to the improved outcomes in this high risk co-
hort of patients. Community transplant centers may contribute in
the future to meet the increased demands for allogeneic HCT with
reasonable outcomes.
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PRELIMINARY RESULTS OF PHASE II TRIAL OF CLOFARABINEWITH PAR-
ENTERAL BUSULFAN (CLO/BU) FOLLOWED BY ALLOGENEIC RELATED
OR UNRELATED DONOR TRANSPLANTATION FOR THE TREATMENT OF
HEMATOLOGIC MALIGNANCIES
Agura, E.1,2, Berryman, R.B.1,2, Pineiro, L.1,2, Vance, E.1,2, Tadic-
Ovcina, M.1, Woelfel, R.G.1, Fay, J.1,2 1Charles A Sammons Cancer
Center, Baylor University Medical Center, Dallas, TX; 2Charles A
Sammons Cancer Center, Texas Oncology P.A., Dallas, TX
BACKGROUND: RIT regimens are common, but relapse remains
a problem. We proposed and tested a mid-intensity regimen using
clofarabine (CLO) with busulfan (BU).We hypothesized this combo
would be well tolerated and offer greater anti-leukemic efficacy than
existing RIT regimens.
METHODS:We enrolled 20 patients on this single IST, with AML
(10), ALL (1), CLL (1),MDS (2) andMDS-AML (6). 15 patients had
prior therapies. The regimenwas: CLO40mg/m2 iv daily x5, BU 3.2
mg/kg iv daily x2, followed by 1 rest day, followed byHSCT.Donors
were matched at A, B, C, DR, DQ usingDNA SBT or mid-res DNA
typing. Mismatch# 1 antigen was allowed. GVHD prophylaxis was
FK506 and MTX 5mg/m2 iv (d 1,3,6).
RESULTS: Endpoints included toxicity, engraftment, incidence/
severity of AGVHD, and disease response.
All patients experienced grade 4 hem tox.Median time to ANC re-
covery (18/20 patients used GCSF) was 13 days (d9 - d17). Engraft-
ment (. 80% donor chim. at d30) occurred in all patients by FISH
and/or STR. Selected tox. included; 2 patients - hand/foot syndrome
(1 Gr. 3, REL.); 1 resp. failure (Gr. 3 poss. REL) resolved com-
pletely; 5 patients - elevated ALT/AST (Gr.3-4, REL) resolving at
regimen completion; other tox. were#Gr. 2. TRMwas non-existent
in this study.
18 patients developed AGVHD by d100 – 83% grade 1-2; 17%
grade 3-4. No deaths attributed to AGVHD following study regi-
men.
Disease responses are: 11 (58%) patients, in relapse/active disease
prior to CLO/BU, achieved CR by d30. 7 (37%) patients in CR at
study entry, remained so at d30. 1 patient was N/E for disease re-
sponse at d30. 1 patient (w / CLL) achieved CR at d132. 7 (37%) pa-
tients relapsed (M. d120 (d60 – d699)). 12 (60%) patients expired (M.
d222 (d92 – d438)): cardiac arrest (1, d316); asp. pneumonia (1,
d158); TTP (1, d438); AGVHD - post DLI (1, d175); relapse (4,
M. d192 (d150 – d415)); persistent disease (1, d161); MSOF (1,
d92); ITP (1, d307); Pulmonary Embolus (1, d233). Of 19 evaluable
patients, 6 (32%) remain in remission with a median follow up of 946
days (31 months) (d396 – d1236).
Poster Session II S299CONCLUSIONS: CLO/BU is a mid-intensity allo HSCT regi-
men with promising anti-leukemic efficacy that seems to be well tol-
erated without significant cardiac, renal or pulmonary toxicities.
CLO/BU resulted in full engraftment by day 30 in all patients. En-
rolment is closed; data collection/analysis is ongoing to determine
the practicality of this regimen being studied in a multicenter
comparative clinical trial.
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MYELOABLATIVE CONDITIONINGWITH INTRAVENOUS BUSULPHAN IN A
SINGLE DAILY DOSE AND FLUDARABINE (BUF) FOR HLA-IDENTICAL
SIBLING ALLOGENEIC HSCT IN MYELOID MALIGNANCIES
De la Serna, J.1, Bermudez, A.2, Sanz, J.3, Caballero, D.4, De la
Camara, R.5, Vallejo, C.6, Serrano, D.7, Moraleda, J.M.8,
Benlloch, L.9, Sanz, G.3 1Hospital 12 de Octubre, Madrid, Spain;
2Hospital Valdecilla, Santander, Spain; 3Hospital La Fe, Valencia, Spain;
4Hospital Clinico, Salamanca, Spain; 5Hospital de la Princesa, Madrid,
Spain; 6Hospital Central, Asturias, Spain; 7Hospital G. Mara~non,
Madrid, Spain; 8Hospital V. Arrixaca, Murcia, Spain; 9GETH, Spain
Background:There is a need to improve the conditioning regimens
for allogeneic HSCT, reducing the regimen related toxicity while
maintaining the anti-leukemic effect. The combination of myeloa-
blative doses of intravenous busulphan (BU) with fludarabine (F)
has been utilized with an improved safety profile.
Objective:We aimed to test the efficacy and safety of this combina-
tion (BUF), with a single daily dose of BU, since prior pharmacologic
and clinical studies support its safety compared with standard 4-daily
doses.
Patients: Sixty seven consecutive adult patients undergoing HLA
identical sibling allogeneicHSCT formyeloidmalignancies were re-
cruited from eight Spanish institutions. Their main characteristics
are shown in table 1.
Table 1. Patients characteristicsPATIENTS 67
Age: median (range) years 45 (17-74)
Patients aged > 55 years 30%
Male gender 58%
DISEASE
AML 35 (52.2%)
MDS Intermediate/High risk 21 (31.3%)
Secondary AML 5 (7.5%)
Myeloproliferative disorder 6 (9%)Conditioning regimen consisted in BU, one daily IV infusion (3.2
mg/kg/d) for 4 days (total dose 12.8 mg/kg), combined with F, 40
mg/m2 daily (total dose 160 mg/m2). GVHD prophylaxis consisted
in cyclosporine and methotrexate. Antimicrobial and other support-
ive measures were followed at each institution policies. Donor graft
source was PB in 76% and BM in 24% of cases. Median CD34 cells
infused were 4.0 mill/kg (0.6-17).
Results: All but one patient engrafted, with a median of 14 days (8-
34) for 0.5 granulocytes and 12 days (7-46) for 20 platelets.Main tox-
icities (Bearman) were grade 1. Major toxicity was mucositis (Grade
2 or 3, 38%of cases). There were 3 grade-2 VOD cases (4.5%) which
resolved. Acute GVHD grade 2-4 incidence was 22%. Day-100 ac-
cumulated mortality was 4.5%. The median follow-up of this ongo-
ing study is 14 months (3-51). At the time of this interim analysis, the
relapse free survival is 79.8% and overall survival 80.7%. Major
causes of death were relapse (59%) and infection or toxicity (35%).
In conclusion, in the HLA identical allogeneic HSCT setting BUF
provides excellent tumour control and low transplant related toxicity
and mortality. In particular, the incidence of VOD is\ 5%.
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IMPACT OF INJECTION VOLUME AND INFUSION RATE IN A LARGE ANI-
MAL MODEL DESIGNED TO OPTIMIZE INTRABONE TRANSPLANTATION
OF HEMATOPOIETIC STEM CELLS
Pantin, J.M.1, Robert, H.F.2, Chen,M.Y.3, Timothy, H.2, Randall, C.R.2,
Childs, R.W.1 1National Institutes of Health, Bethesda, MD; 2National
Institutes of Health, Bethesda, MD; 3National Institutes of Health,
Bethesda, MDBackground: The intrabone (IB) route of stem cell administration
results in improved engraftment in murine models of transplanta-
tion. However, human clinical trials have yet to establish that hema-
topoietic stem cell (HSC) engraftment is improved with the use of IB
delivery. The use of IB vascular access can rapidly restore systemic
blood volume and pressure in shock situations, although this access
route can be associated with pulmonary emboli. Furthermore, both
pressure and shear stress, which have not been characterized with
conventional IB delivery techniques, may damage HSCs compro-
mising their ability to engraft. Murine models do not have compar-
ative anatomy or physiology to predict the dynamics ofHSC delivery
in humans following IB injection. In contrast, swine have similar car-
diovascular physiology and size analogous to humans and can be
used as a model to study the fluid dynamics of IB injection.
Methods: Forty-five to 60 kg domestic swine were placed under
general anesthesia with IB access of the pelvis achieved using an On-
Control driver (Vidacare). Isovue was injected into the pelvis at vary-
ing volumes and rates and the entire pelvis was imaged by 320-slice
ultrafast continuous dynamicCT (Toshiba Aquilion). Pulmonary ar-
tery, carotid artery and intramarrow cavity pressures weremonitored
continuously both during and after injection into the pelvis.
Results:Wefirst characterized the comparative vascular anatomy of
the porcine pelvis. Themajor arterial blood supply to the pelvic bone
marrow was found to arise from branches of the internal iliac artery
with venous drainage occurring through the iliac vein. IB injection of
contrast led to an immediate systemic delivery into the central ve-
nous circulation. Reducing the infusion volume and slowing the
rate of the infusion both produced smaller increases in IB marrow
pressure and post-injection peak pulmonary artery systolic pressure
(PASP).
Table 1. Post IB Injection Changes in Intramarrow pressure
and Peak PASP
D Peak PulmonaryVolume
Injected (mL)Rate
Injected
(mL/s)Number of
InfusionsD Intramarrow
Pressure
(mmHg)
Mean ± S.E.Artery Systolic
Pressure
(PASP) (mmHg)
Mean ± S.E.10 0.1 4 159.3 ± 57.7 1.5 ± 0.7
10 0.2 3 300.3 ± 149.3 3.5 ± 1.0
10 0.5 2 803.4 ± 483.0 13.0 ± 5.1
10 1.0 2 1196.0 ± 265.5 8.9 ± 9.3
10 2.5 3 1689.0 ± 116.0 2.2 ± 1.0
5 0.1 2 128.7 ± 60.2 -0.5 ± 0.4
5 0.2 2 256.7 ± 42.7 1.3 ± 1.3
5 0.5 1 802.9 6.1
5 1.0 1 1490.8 0
5 2.5 1 997.5 2Conclusions: The IB route of injection provides rapid access to the
central venous circulation. Increasing IB infusion volumes and/or IB
infusion rates led to profound increases in intramarrow pressures and
significantly increases PASP. These data suggest continuous moni-
toring of IB pressures is necessary for studies aimed at characterizing
stem cell trafficking and to optimize the retention of HSC in the
intrabone marrow space following IB injection.402
VARICELLA ZOSTER REACTIVATION AFTER CORD BLOOD TRANSPLANTA-
TION: COMPARISON WITH UNRELATED BONE MARROW TRANSPLANTA-
TION
Asano-Mori, Y.1, Nishida, A.1, Ikebe, T.1, Ishiwata, K.1, Nakano, N.1,
Tsuji, M.1, Yamamoto, H.1, Izutsu, K.1, Uchida, N.1, Masuoka, K.2,
Wake, A.1, Yoneyama, A.3, Makino, S.4, Taniguchi, S.1 1Toranomon
Hospital, Tokyo, Japan; 2Mishuku Hospital, Tokyo, Japan; 3Toranomon
Hospital, Tokyo, Japan; 4Toranomon Hospital, Tokyo, Japan
Varicella zoster virus (VZV) infection remains an important prob-
lem after allogeneic hematopoietic stem cell transplantation, because
VZV-related complications including post-herpetic neuralgia
